SELLAS Life Sciences Group, Inc. Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
SELLAS Life Sciences Group, Inc. (SLS) reported Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-23.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions · last filed 2021-03-23
- SELLAS Life Sciences Group, Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- SELLAS Life Sciences Group, Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2019 was $55.00K, a 223.53% increase from fiscal 2018.
- SELLAS Life Sciences Group, Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2018 was $17.00K.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-23 |
| 2019-12-31 | $55.00K 10-K · filed 2021-03-23 |
| 2018-12-31 | $17.00K 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |